How should a patient currently taking Victoza (liraglutide) 1.8 mg daily switch to Rybelsus (oral semaglutide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Switching from Victoza 1.8mg to Rybelsus

Stop Victoza and start Rybelsus at 3 mg once daily the next morning, following strict administration instructions: take on an empty stomach with up to 4 ounces of plain water only, then wait at least 30 minutes before eating, drinking, or taking other medications. 1

Dosing Transition Protocol

When switching from Victoza (liraglutide) 1.8 mg subcutaneous daily to Rybelsus (oral semaglutide):

Day 1-30:

  • Start Rybelsus 3 mg once daily (this is a tolerability dose, not effective for glycemic control)
  • Discontinue Victoza immediately—no overlap or washout period needed

Days 31-60:

  • Increase to Rybelsus 7 mg once daily

Day 61 onwards:

  • If additional glycemic control is needed, increase to 14 mg once daily
  • If 7 mg provides adequate control, maintain that dose 1

Critical Administration Requirements

Rybelsus has unique absorption requirements that are non-negotiable for efficacy:

  • Take first thing in the morning on a completely empty stomach
  • Use no more than 4 ounces (120 mL) of plain water only—no other beverages
  • Swallow whole—do not split, crush, chew, or dissolve
  • Wait at least 30 minutes before consuming any food, beverages, or other oral medications
  • Taking with food or other liquids will significantly reduce absorption 1

Expected Outcomes

The PIONEER 4 trial directly compared oral semaglutide 14 mg with subcutaneous liraglutide 1.8 mg and demonstrated:

  • Superior glycemic control: Oral semaglutide reduced HbA1c by -1.2% vs -1.1% with liraglutide (non-inferior, and superior when accounting for treatment adherence)
  • Greater weight loss: -4.4 kg with oral semaglutide vs -3.1 kg with liraglutide (difference of -1.2 kg, p=0.0003)
  • Similar tolerability: Adverse events occurred in 80% with oral semaglutide vs 74% with liraglutide, predominantly gastrointestinal 2

Managing the Transition

Gastrointestinal symptoms are the most common issue during GLP-1 RA therapy:

  • The 3 mg starting dose for 30 days helps mitigate nausea and vomiting
  • Patients already on liraglutide 1.8 mg may have better GI tolerance than GLP-1 RA-naive patients
  • If severe GI symptoms occur, the dose escalation timeline can be extended beyond the standard 30-day intervals 1

If doses are missed:

  • Resume at the next scheduled dose—do not double up
  • If more than 3 days missed, consider restarting at 3 mg to reduce GI symptoms 1

Monitoring Considerations

Both medications are GLP-1 receptor agonists with similar safety profiles 3:

  • No renal dose adjustment required for either medication
  • Monitor for diabetic retinopathy complications if the patient has a history
  • Reduce insulin or sulfonylurea doses if used concomitantly to prevent hypoglycemia
  • Watch for signs of pancreatitis, gallbladder disease, or acute kidney injury from volume depletion 1

Contraindications

Rybelsus shares the same contraindications as Victoza:

  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Prior serious hypersensitivity to semaglutide 1

Practical Advantages

The switch to oral semaglutide offers:

  • No injections—may improve adherence and patient satisfaction
  • Once-daily dosing maintained (same as Victoza)
  • Superior efficacy for both glucose control and weight loss 2
  • Cardiovascular safety demonstrated (non-inferior to placebo in high-risk patients) 4

The key to success is strict adherence to the unique administration requirements—this cannot be overemphasized with patients, as improper administration will result in treatment failure.

References

Related Questions

Do Rybelsus (semaglutide) or glipizide cause glucosuria?
What is the appropriate dosing regimen for liraglutide and semaglutide injections for this treatment?
Can liraglutide (Victoza) and semaglutide (Ozempic) injections be taken with or without food?
Can Rybelsus (semaglutide) be used for insulin resistance?
Is Rybelsus (oral semaglutide) still available for treatment?
What is the appropriate method to switch a patient who was on Invega 156 mg intramuscular, then switched to Risperdal (risperidone) 2 mg twice daily, back to oral Invega (paliperidone)?
In a postoperative adult >2 weeks after superior mesenteric vein thrombosis with bowel resection and ileostomy, who now has persistent orthostatic hypotension with a ~60 mm Hg systolic drop on sitting, episodes of sudden blood pressure fall with diaphoresis, normal echocardiogram, normal cortisol, high‑output ileostomy (~2.5 L/day) with neutral fluid balance, and is on fludrocortisone 100 µg daily while being weaned from norepinephrine, what is the appropriate further management and can this be diagnosed as afferent baroreceptor failure?
For an 80-year-old man with moderate dementia (SLUMS score 10), hypertension, iron-deficiency anemia, hyperlipidemia, currently taking losartan‑hydrochlorothiazide, atorvastatin, iron with vitamin C, and metoprolol succinate extended-release, who discontinued memantine because it made him mean, what medication can be started for his dementia besides referral to neurology?
What is the recommended follow-up and surveillance plan for an incidentally identified gastrointestinal stromal tumor (GIST) discovered on colonoscopy?
In an 89‑year‑old female with chronic urinary tract infections, recent low‑grade fevers, fatigue, altered taste, increased thirst, intermittent urinary leakage, dysuria, and trace leukocytes on urinalysis after starting amlodipine, how should the results be interpreted and what is the appropriate treatment plan?
What is the appropriate next step for a 10-year-old child with urticaria from lying on the ground who is not responding to topical hydrocortisone cream?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.